Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis
| Autor: | Taymaa May, Rouhi Fazelzad, Xuan Li, Soyoun Rachel Kim, Theodore J. Brown, Rebecca M. Goldberg |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Ovarian Neoplasms
Oncology medicine.medical_specialty Chemotherapy integumentary system business.industry medicine.medical_treatment MEDLINE Obstetrics and Gynecology Cytoreduction Surgical Procedures Disease Cystadenocarcinoma Serous Serous fluid Systematic review nervous system Meta-analysis Internal medicine Cohort medicine Humans Female Neoplasm Recurrence Local Prospective cohort study business |
| Zdroj: | Gynecologic Oncology. 164:212-220 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/j.ygyno.2021.10.080 |
| Popis: | Objectives Low-grade serous ovarian cancer (LGSC) is a relatively chemo-resistant disease with limited effective treatment options for patients with recurrence. Secondary cytoreductive surgery (SCS) is commonly offered at recurrence, although any benefit this has on survival is not fully determined. This review evaluates the impact of SCS, including residual disease, on progression-free survival (PFS) and overall survival (OS) in recurrent LGSC. Methods A comprehensive search of Medline ALL, Embase Classic + Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science was conducted to obtain studies evaluating optimal or complete SCS versus suboptimal SCS and the amount of residual disease in recurrent LGSC. Meta-analysis was performed and PFS and OS outcomes were calculated. Results 1Of 5296 studies screened, 350 progressed to full-text review, with 9 ultimately selected for inclusion in the systematic review. Two studies met criteria for meta-analysis of PFS and of OS. The presence of visible residual disease at the conclusion of SCS negatively impacted PFS (HR = 3.51, 95% CI = 1.72-7.14), whereas SCS with no residual disease significantly improved OS (HR = 0.4, 95% CI = 0.23-0.7) in patients with recurrent LGSC. Diffuse and extensive disease distribution was inversely linked to survival. In addition, SCS as an initial treatment for recurrent LGSC was associated with superior survival in comparison to chemotherapy. A short platinum-free interval was not associated with worse survival in this cohort. Conclusions Complete SCS, and to a lesser extent optimal SCS, are associated with improved PFS and OS in patients with recurrent LGSC. SCS may be a better initial treatment strategy than systemic chemotherapy for recurrent disease. Patients with recurrent LGSC should be evaluated for the role of SCS based on disease distribution and functional status, irrespective of the platinum-free interval. Prospective studies are needed to further study the role of SCS in patients with recurrent LGSC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect